our Human Resources policy

RESOURCES

Circle Oncodesign Services

The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.

Filter by category
  • All
  • Blog
  • Congress
  • Scientific resource
  • Webinar
  • Poster
  • Scientific publication
  • Press release
  • Press coverage
  • News
Filter by category
Circle Oncodesign Services
Press release
30/09/2022

The General Meeting of Oncodesign authorises the allocation of OPM

Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held

Financial Press Release | Oncodesign
Press release
28/09/2022

Euronext Paris authorises the listing of OPM shares

Oncodesign Precision Medicine (OPM) and Oncodesign announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access + market in Paris of OPM’s ordinary shares.

Press release
26/09/2022

Servier exercises the exclusive worldwide license option of their collaboration program LRRK2

Servier and Oncodesign Precision Medicine (OPM) announce that Servier has exercised its exclusive license option for their drug candidate

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Press release
22/09/2022

OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment

Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement

Poster
02/09/2022

Lewis acid catalyzed chemoselective and regioselective epoxide ring opening with sulfoximines

We report Sulfoximines with the first regioselective Epoxide Ring opening; these findings broaden their Drug Discovery and design applications. Read more.

notre-management
Press release
01/07/2022

ONCODESIGN announces the separation of its two business lines – Service and Biotech

ONCODESIGN today announced that the Board of Directors has approved the subsidiarisation of its Biotech business.

Scientific paper - Ressources
Poster
29/06/2022

In vitro pharmacological profile of Compound A

Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease.

Scientific paper - Ressources
Poster
29/06/2022

In vivo PK/PD profile of Compound A

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.

Parkinson's disease | Oncodesign
News
11/04/2022

Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need

Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!

Scientific paper - Ressources
Poster
08/04/2022

Mouse models of hepatocellular carcinoma

Get to know more about our comprehensive & functional preclinical platform for immunotherapy research using mouse models (PDX, human transgenic mouse).

Scientific paper - Ressources
Poster
08/04/2022

Using individual or a consortium of bacteria for immuno-oncology research

Get to know more about the beneficial role of bacteria for cancer therapy. Oncodesign Services, vector Of Innovation in oncology, inflammation & Covid-19.